Benzinga | Oct 19, 2021 03:49PM EDT

ImmunityBio Meets Endpoint In Second Indication Cohort In Bladder Cancer Trial

* ImmunityBio Inc (NASDAQ:IBRX) has announced that Papillary disease (Cohort B) of its Phase 2/3 study of intravesical BCG plus Anktiva met its primary endpoints with disease-free survival of 57% at 12 months.

* Non-muscle invasive bladder cancer (NMIBC) makes up 75%-85% of all bladder cancers in the U.S.; approximately 90% of NMIBC cases are papillary.

* Related: ImmunityBio Announces Updated Data From Ongoing Bladder Cancer Trial Showing Complete Response Rate Of 72%.

* To date, 73 patients have enrolled in Cohort B with a median follow-up of 17.3 months.

* At 18-months, the disease-free survival rate was 53%. Durable responses were noted.

* There were zero immune- or treatment-related severe adverse events noted in the combined safety analysis of 154 patients in the trial.

* Key patent allowed covering Anktiva intravesical use in bladder cancer with the term extending to 2035.

* Price Action: IBRX shares are up 2.52% at $9.16 during the market session on the last check Tuesday.